[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632086":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":106,"collaborators":20,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":110,"sex":115,"minAge":116,"maxAge":20,"enrollmentInfo":117,"targetDuration":20,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":136,"whyStopped":20,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"Kirby Institute","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Adults with methamphetamine use disorder","EXPERIMENTAL","12 weeks of subcutaneous semaglutide administered once weekly",[13],"Drug: 12 weeks of weekly subcutaneous semaglutide injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","12 weeks of weekly subcutaneous semaglutide injection","12 weeks of subcutaneous semaglutide administered once weekly, starting at 0.25 mg once weekly, titrated as tolerated up to 1.0 mg over the 12-week study period.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"David Goodman-Meza, MD, PhD","CONTACT","+61 2 9385 0900","shiftstudy@unsw.edu.au",[28,48,58,74,90],{"facility":29,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Kirketon Road Centre","Darlinghurst","New South Wales","2010","Australia","AU",{"type":36,"coordinates":37},"Point",[38,39],151.21925,-33.87939,{"lat":39,"lon":38},[42,46],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Phillip Read","+61 2 9360 2766","Phillip.Read1@health.nsw.gov.au",{"name":43,"role":47,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":49,"status":20,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":50,"geoPoint":52,"contacts":53},"Rankin Court Treatment Centre, St Vincent's Hospital Sydney",{"type":36,"coordinates":51},[38,39],{"lat":39,"lon":38},[54,56],{"name":23,"role":24,"phone":20,"phoneExt":20,"email":55},"dgoodman@kirby.unsw.edu.au",{"name":57,"role":47,"phone":20,"phoneExt":20,"email":20},"David Goodman-Meza",{"facility":59,"status":20,"city":60,"state":61,"zip":62,"country":33,"countryCode":34,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Alcohol & Drug Service, Metro Health North Brisbane","Brisbane","Queensland","4000",{"type":36,"coordinates":64},[65,66],153.02809,-27.46794,{"lat":66,"lon":65},[69,73],{"name":70,"role":24,"phone":71,"phoneExt":20,"email":72},"Mark Daglish","+617 3837 5764","mark.daglish@health.qld.gov.au",{"name":70,"role":47,"phone":20,"phoneExt":20,"email":20},{"facility":75,"status":20,"city":76,"state":77,"zip":78,"country":33,"countryCode":34,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Drug and Alcohol Services, South Australia","Morphett Vale","South Australia","5162",{"type":36,"coordinates":80},[81,82],138.51667,-35.13333,{"lat":82,"lon":81},[85,89],{"name":86,"role":24,"phone":87,"phoneExt":20,"email":88},"Katherine Senior","+618 8325 8111","Katherine.Senior@sa.gov.au",{"name":86,"role":47,"phone":20,"phoneExt":20,"email":20},{"facility":91,"status":20,"city":92,"state":93,"zip":94,"country":33,"countryCode":34,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Next Step Drug and Alcohol Services","East Perth","Western Australia","6004",{"type":36,"coordinates":96},[97,98],115.87109,-31.95872,{"lat":98,"lon":97},[101,105],{"name":102,"role":24,"phone":103,"phoneExt":20,"email":104},"Michael Christmass","+6189430 5966","michael.christmass@health.wa.gov.au",{"name":102,"role":47,"phone":20,"phoneExt":20,"email":20},{"type":107,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100632086","phase-2-semaglutide-for-treatment-of-people-with-methamphetamine-use-disorder-the-shift-study-100632086",false,"NCT07509112","Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study","SHIFT","Inclusion Criteria:\n\n1. Has provided voluntary, written informed consent;\n2. Aged 18 years or older;\n3. Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria);\n4. Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine\u002Fmethamphetamine;\n5. Willing and able to comply with study procedures and follow-up visits;\n6. People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end.\n\nExclusion Criteria:\n\n1. Uncontrolled medical or psychiatric conditions that may interfere with participation;\n2. Body mass index less than 22 kg\u002Fm2;\n3. Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c \\>6.5 at screening);\n4. Currently taking a GLP-1 receptor agonist;\n5. Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information;\n6. Current enrolment in another interventional trial;\n7. Lactating, pregnant or at risk of pregnancy not willing to avoid pregnancy\n8. History of pancreatitis;\n9. History of medullary thyroid cancer;\n10. Current admission to a residential rehabilitation program or inpatient program or planned admission during the study period, which would interfere with participation in study visits or procedures;\n11. Currently experiencing psychosis or current active suicidality\n12. Any condition or circumstance that, in the opinion of the investigator, would compromise the participant's ability to comply with the study procedures, complete protocol requirements, or provide reliable data.","ALL","18 Years",{"count":118,"type":119},40,"ESTIMATED","INTERVENTIONAL",[122],"PHASE2","Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.",[125],"Methamphetamine Use Disorder",[127,128,129,130,131,132,133,134,135],"Substance use disorder","Addiction","Drug use","Methamphetamine","Stimulants","GLP-1","Semaglutide","Ozempic","Wegovy","NOT_YET_RECRUITING","2026-06-23",{"date":139,"type":140},"2026-06-26","ACTUAL",{"date":142,"type":119},"2026-09",{"date":144,"type":119},"2027-03",{"name":5,"class":6},5]